Breast Cancer | Specialty

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Q&A: Practical Considerations in HER2+ Breast Cancer

September 24th 2020

The Impact of Subcutaneous Option for HER2+ BC

September 24th 2020

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

September 24th 2020

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

September 24th 2020

Administration of Dual HER2-Targeted Therapy in BC

September 24th 2020

Dual HER2-Targeted Approaches in Breast Cancer

September 24th 2020

Historic Perspectives on HER2+ Breast Cancer

September 24th 2020

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Management of Adverse Effects in R/R HER2+ mBC

September 23rd 2020

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

September 23rd 2020

HER2-targeted Therapy: Routes of Administration

September 23rd 2020

Practical Management of Early Stage HER2+ Breast Cancer

September 23rd 2020

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

September 21st 2020

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

September 21st 2020

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Significant Improvement in PFS Seen With Palbociclib/Fulvestrant in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer

September 21st 2020

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.

Tucatinib Regimen Maintains Health-Related QoL in HER2+ Metastatic Breast Cancer

September 21st 2020

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast Cancer

September 20th 2020

Stephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.

Abemaciclib Reduces the Risk of Recurrence in High-Risk Early Breast Cancer

September 20th 2020

The addition of abemaciclib to endocrine therapy led to a significant reduction in the risk of invasive disease versus endocrine therapy alone in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.

Dose-Dense iddEPC Demonstrates Significant Benefits in HR+/HER2- Breast Cancer

September 20th 2020

Neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide demonstrated significant benefit in the treatment of patients with HR+/HER2- breast cancer.